Cargando…

Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia

Mostrar otras versiones (1)

BACKGROUND: TP53 mutations (TP53(MT)) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic, questioning the presence of cryptic biallelic subclones in cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahaj, Waled, Kewan, Tariq, Gurnari, Carmelo, Durmaz, Arda, Ponvilawan, Ben, Pandit, Ishani, Kubota, Yasuo, Ogbue, Olisaemeka D., Zawit, Misam, Madanat, Yazan, Bat, Taha, Balasubramanian, Suresh K., Awada, Hussein, Ahmed, Ramsha, Mori, Minako, Meggendorfer, Manja, Haferlach, Torsten, Visconte, Valeria, Maciejewski, Jaroslaw P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029089/ https://www.ncbi.nlm.nih.gov/pubmed/36945617 http://dx.doi.org/10.21203/rs.3.rs-2656206/v1

Ejemplares similares

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
por: Bahaj, Waled, et al.
Publicado: (2023)

Molecular patterns identify distinct subclasses of myeloid neoplasia
por: Kewan, Tariq, et al.
Publicado: (2023)

New approaches to idiopathic neutropenia in the era of clonal hematopoiesis
por: Ogbue, Olisaemeka D., et al.
Publicado: (2023)

Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
por: Mori, Minako, et al.
Publicado: (2023)

Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease
por: Zawit, Misam, et al.
Publicado: (2021)

A multimodal analysis of genomic and RNA splicing features in myeloid malignancies
por: Durmaz, Arda, et al.
Publicado: (2023)

Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value
por: Pagliuca, Simona, et al.
Publicado: (2022)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes
por: Awada, Hussein, et al.
Publicado: (2022)

Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives
por: Ogbue, Olisaemeka, et al.
Publicado: (2023)

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation
por: Pagliuca, Simona, et al.
Publicado: (2021)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
por: Meggendorfer, Manja, et al.
Publicado: (2017)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Hepatitis C Infection Associated with Acquired Pure Red Cell Aplasia
por: Teague, Destini, et al.
Publicado: (2022)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
por: Attardi, Enrico, et al.
Publicado: (2023)

Spermatic Cord Liposarcoma: A Case Report and Review of the Literature on the Role of Radiotherapy and Chemotherapy in Preventing Locoregional Recurrence
por: Ogbue, Olisaemeka D, et al.
Publicado: (2021)

A Rare Case of Emphysematous Gastritis Secondary to Chemotherapy
por: Ogbue, Olisaemeka D, et al.
Publicado: (2021)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
por: Höllein, Alexander, et al.
Publicado: (2019)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia
por: Walter, Wencke, et al.
Publicado: (2021)

S161: UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
por: Sakuma, Maki, et al.
Publicado: (2023)

P690: IDENTIFICATION OF CLINICALLY RELEVANT VARIANT-LEVEL SEX-BIAS IN SF3B1 K700/K666 AND IDH2 R140/R172
por: Sakuma, Maki, et al.
Publicado: (2023)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?
por: Baer, Constance, et al.
Publicado: (2019)

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis
por: Müller, Heiko, et al.
Publicado: (2022)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
por: Huber, Sandra, et al.
Publicado: (2022)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes
por: Ogbue, Olisaemeka, et al.
Publicado: (2022)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_879dip3otd5uqt3fv581nskroi